Effect of PD-1 inhibitor combined with chemotherapy on cytokines and immune cell function in patients with advanced lung cancer

Read full text Summarise with VIRAT
Authors: Chenxin Zhang, Jiqing Hao
Cited by: 0
References: 5

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective To investigate the regulatory effects of PD-1 inhibitor combined with chemotherapy on peripheral blood cytokine levels and immune cell function in patients with advanced lung cancer. Methods A retrospective study was conducted on patients with advanced lung cancer admitted to our hospital from January 2022 to May 2025, including 68 cases in the combination therapy group (PD-1 inhibitor combined with pemetrexed/paclitaxel-based chemotherapy) and 34 cases in the chemotherapy group. Among the combination therapy group, there were 46 cases of lung adenocarcinoma and 22 cases of lung squamous cell carcinoma; in the chemotherapy group, there were 24 cases of lung adenocarcinoma and 10 cases of lung squamous cell carcinoma. The combination therapy group received a chemotherapy regimen based on pemetrexed/paclitaxel, combined with sintilimab, camrelizumab, or tislelizumab (all at 200 mg per cycle), while the chemotherapy group received only chemotherapy. Both groups were treated for more than 2 cycles, with 3 weeks as one cycle. Peripheral blood T-cell subsets, NK cell-related indicators, and serum cytokine levels were measured before treatment and after 2 cycles of treatment in both groups, and changes and intergroup differences were analyzed. Results After treatment, immune cell-related indicators (CD3+%, CD3 + CD8+%, NK cell proportion, etc.) and cytokine levels (e.g., elevated IL-2, decreased IL-6 and IL-8) in both groups showed significant improvement compared to pre-treatment levels (P < 0.05), but the improvement in the combination therapy group was significantly greater than that in the chemotherapy group (P < 0.05). Subgroup analysis revealed that the increase in CD3 + CD8+% was higher in lung squamous cell carcinoma patients than in lung adenocarcinoma patients in the combination therapy group (P < 0.05), and EGFR-TKI resistance and driver gene negativity were also observed.There was no significant difference in the decline of IL-6 levels among patients (P > 0.05). Conclusion The combination of PD-1 inhibitors and chemotherapy improves immune cell function and positively regulates cytokines in advanced lung cancer patients more effectively than chemotherapy alone. This approach demonstrates favorable immunomodulatory effects across different pathological types and EGFR-TKI-resistant patients, potentially providing a basis for precision therapy. Relevant immune and cytokine markers may serve as potential predictive biomarkers for treatment efficacy and prognosis.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies Lung Cancer Treatments and Mutations

Publication details

Journal / source
Research Square
Publication date
31 March 2026
Language
EN
Document type
Preprint